A 58-year-old man with chronic kidney disease (eGFR 28 mL/min/1.73 m²) presents with hemoglobin 8.5 g/dL, MCV 88 fL, and normal iron studies. Reticulocyte count is 0.8% (low). What is the drug of choice for managing his anemia?

Explanation

## Anemia of Chronic Kidney Disease — ESA Therapy ### Clinical Diagnosis The patient has **anemia of chronic kidney disease (CKD)** characterized by: - **Normocytic, normochromic anemia** (MCV 88 fL; normal 80–100 fL) - **Low reticulocyte count** (0.8%; normal 0.5–2.5%) → inadequate bone marrow response - **Normal iron studies** → iron deficiency excluded - **Advanced CKD** (eGFR 28 mL/min/1.73 m²) → reduced erythropoietin (EPO) production ### Pathophysiology **Key Point:** In CKD, the kidneys fail to produce adequate erythropoietin (EPO), the primary stimulus for RBC production. This results in normocytic anemia with a blunted reticulocyte response despite adequate iron and B12 stores. ### First-Line Treatment: ESA **High-Yield:** Erythropoietin-stimulating agents (ESAs) are the first-line pharmacological treatment for anemia of CKD when hemoglobin falls below 10 g/dL or when the patient is symptomatic. ### ESA Options & Dosing | ESA Agent | Route | Dosing | Half-life | |-----------|-------|--------|----------| | **Epoetin alfa (recombinant human EPO)** | IV or SC | 50–100 units/kg 3× weekly | 4–13 hours | | **Darbepoetin alfa (long-acting ESA)** | IV or SC | 0.45 μg/kg weekly or 0.75 μg/kg every 2 weeks | 21 hours | | **Peginesatide** | IV | 0.04 mg/kg monthly | 40–50 hours | **Clinical Pearl:** In dialysis patients, IV administration is preferred (via dialysis line). In non-dialysis CKD, subcutaneous administration is acceptable and may require lower doses. ### Target Hemoglobin **Warning:** Avoid over-correction. Current guidelines recommend: - **Target Hb: 10–12 g/dL** (not >12 g/dL) - Over-correction increases cardiovascular events, stroke, and thrombosis - Individualize target based on age, comorbidities, and symptoms [cite:KDIGO 2021 Anemia in CKD Guidelines] ### Monitoring & Safety **Tip:** Monitor: - Hemoglobin every 1–2 weeks during initiation; then monthly once stable - Blood pressure (ESAs can elevate BP) - Iron stores (ferritin, transferrin saturation) — maintain adequate iron - Thrombotic events (DVT, stroke, MI) ### When to Consider ESA ```mermaid flowchart TD A[CKD patient with anemia]:::outcome --> B{Hb < 10 g/dL or symptomatic?}:::decision B -->|Yes| C{Iron replete?}:::decision C -->|Yes| D[Start ESA]:::action C -->|No| E[Correct iron deficiency first]:::action B -->|No| F[Observe, monitor Hb]:::action D --> G[Target Hb 10-12 g/dL]:::outcome E --> H[Recheck iron studies]:::action H --> I{Iron replete now?}:::decision I -->|Yes| D I -->|No| J[Consider IV iron]:::action ``` [cite:KDIGO 2021 Anemia in CKD Guidelines]